SigNature^® T Traceability System to be
Installed in Egypt to Tag Two Cotton Varietals

STONY BROOK, N.Y.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24apdn&src=ctag” target=”_blank”gt;$apdnlt;/agt; lt;a href=”https://twitter.com/hashtag/EgyptianCotton?src=hash” target=”_blank”gt;#EgyptianCottonlt;/agt;–Applied
DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a
leader in PCR-based manufacturing for product authenticity and
traceability solutions, announced today it received an order for the
implementation of its SigNature^® T cotton traceability system
in Egypt to indelibly mark two varietals of high-value Egyptian cotton,
widely acknowledged to be among the finest in the world. The molecular
tag and delivery system have been shipped and cotton tagging is expected
to commence within the month. The system, already installed in eight
cotton gins worldwide, includes the use of unique SigNature T molecular
tags, internet-based data collection linking evidence of tagging process
quality to each bale ID, and bar code scanning of tagged packaged bales
for inventory management and tracking. The cotton fiber will be managed
with strict protocols throughout the supply chain to ensure purity and
traceability.

“With receipt of this order for Egyptian cotton supply chain tagging and
testing, we are moving to replicate our success in securing U.S. cotton
through its supply chain. Given the uncertainty surrounding the
provenance of Egyptian cotton in the marketplace and growing calls for
increased transparency and traceability by consumers, brands and
industry advocates, the implementation of our SigNature T cotton
traceability system endeavors to ensure that the value of Egyptian
cotton can be substantiated throughout its supply chain,” said Dr. James
A. Hayward, president and CEO of Applied DNA.

According to the Mundi
Report, Egypt produced approximately 240 million pounds of cotton in
the prior 2018 growing season, just below total U.S.
Pima output.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply
chain security, anti-counterfeiting and anti-theft technology, product
genotyping and pre-clinical nucleic acid-based therapeutic drug
candidates.

Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect
products, brands, entire supply chains, and intellectual property of
companies, governments and consumers from theft, counterfeiting, fraud
and diversion.

Visit www.adnas.com
for more information. Follow us on Twitter
and LinkedIn.
Join our mailing
list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are
listed under the symbol APDNW.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private Securities
Litigation Act of 1995. Forward-looking statements describe Applied
DNA’s future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and uncertainties,
many of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to our history of net
losses, limited financial resources, limited market acceptance, and
various other factors detailed from time to time in Applied DNA’s SEC
reports and filings, including our Annual Report on Form 10-K filed on
December 18, 2018 and our subsequent quarterly report on Form 10-Q filed
on February 7, 2019, and other reports we file with the SEC, which are
available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly
any forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of
unanticipated events, unless otherwise required by law.

Contacts

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777,
[email protected]
media
contact: Meryl Rader, 781-639-4924, [email protected]
program
contact: MeiLin Wan, Vice President of Sales, 631-240-8849, [email protected]
web: www.adnas.com
twitter:
@APDN